Free tool
FAERS Monitor: Prohance Multipack
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021489 or its brand name (Prohance Multipack, Gadoteridol). Reports on generic versions are filed under their own applications.
Reports
1,816
Serious
1,516
83% of reports
Hospitalization
380
Death reported
162
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nephrogenic systemic fibrosis587
- pain407
- anxiety254
- emotional distress223
- mobility decreased186
- general physical health deterioration184
- fibrosis183
- injury178
- scar159
- skin hypertrophy154
- skin induration151
- pruritus147
- dyspnoea142
- skin tightness137
- nausea131
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 27 |
| 2005 | 28 |
| 2006 | 41 |
| 2007 | 42 |
| 2008 | 47 |
| 2009 | 70 |
| 2010 | 176 |
| 2011 | 208 |
| 2012 | 92 |
| 2013 | 50 |
| 2014 | 121 |
| 2015 | 33 |
| 2016 | 64 |
| 2017 | 78 |
| 2018 | 85 |
| 2019 | 93 |
| 2020 | 85 |
| 2021 | 125 |
| 2022 | 68 |
| 2023 | 63 |
| 2024 | 75 |
| 2025 | 62 |
| 2026 | 83 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,343 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| nephrogenic systemic fibrosisSignal | 587 | 2791.2 | 2583.1 | 1,317,486 |
| skin indurationSignal | 151 | 909.8 | 776.0 | 126,277 |
| fibrosisSignal | 183 | 732.3 | 635.3 | 125,035 |
| skin hypertrophySignal | 154 | 671.4 | 574.5 | 96,826 |
| skin tightnessSignal | 137 | 347.4 | 294.9 | 45,615 |
| scarSignal | 159 | 108.6 | 93.5 | 16,694 |
| mobility decreasedSignal | 186 | 30.1 | 26.2 | 5,201 |
| injurySignal | 178 | 29.4 | 25.6 | 4,858 |
| emotional distressSignal | 223 | 21.4 | 18.9 | 4,327 |
| general physical health deteriorationSignal | 184 | 18.4 | 16.1 | 3,031 |
| anxietySignal | 254 | 10.3 | 9.2 | 2,162 |
| painSignal | 407 | 7.7 | 7.0 | 2,427 |
| pruritusSignal | 147 | 4.4 | 3.8 | 394 |
| dyspnoeaSignal | 142 | 2.9 | 2.5 | 180 |
| nausea | 131 | 1.9 | 1.6 | 59 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.